文献速递临床试验与 GCP基础与转化研究

解毒通络颗粒治疗气虚血瘀型卒中后抑郁的随机对照试验方案

The efficacy and safety of Jiedu Tongluo granules for treating post-stroke depression with qi deficiency and blood stasis syndrome: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-05-10

主要结局为8周后HAMD-17评分较基线下降≥50%或临床痊愈(评分<7),同时评估神经功能、日常生活能力、中医证候及安全性,并监测IL-6、IL-8及小分子代谢物以探索机制。

要点

  • 解毒通络颗粒联合常规治疗用于气虚血瘀型卒中后抑郁,疗程8周。
  • 主要疗效指标为HAMD-17评分下降≥50%或评分<7。
  • 次要指标包括NIHSS、mRS、BI、中医证候量表及IL-6、IL-8等。

核心结论

  • 该试验旨在评估解毒通络颗粒治疗气虚血瘀型卒中后抑郁的疗效与安全性,若成功可为该类患者提供可选治疗方案。

研究设计与样本

  • 治疗组接受解毒通络颗粒联合常规治疗,安慰剂组接受安慰剂联合常规治疗,疗程均为8周。

关键数值与推荐

  • 主要结局为治疗8周后HAMD-17评分较基线下降≥50%或临床痊愈(评分<7)。
  • 次要结局采用NIHSS评估神经功能、mRS评估独立程度、BI评估日常生活活动能力、中医量表评估中医证候。
  • 机制探索指标包括IL-6、IL-8及小分子代谢物。
  • 安全性指标包括生命体征、心电图、实验室指标(全血细胞计数、肝肾功能)及不良事件。

临床怎么用

  • 该方案尚处于试验阶段,结果未报告,暂不能形成临床推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-stroke depression (PSD) is the most common psychiatric complication after a stroke. The most frequently used antidepressants are selective serotonin receptor inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), however, these exhibit a series of side effects. Traditional Chinese medicine has been used to treat PSD with few side effects. The aim of this study is to evaluate the efficacy and safety of Jiedu Tongluo granules for treating PSD with qi deficiency and blood stasis syndrome. METHODS: The planned study is a double-blind, randomized, placebo-controlled pilot trial. Eighty participants will be randomly assigned to receive either treatment or placebo. The treatment group will receive Jiedu Tongluo granules (JDTLG) with conventional treatment, and the placebo group will receive placebo with conventional treatment for 8 weeks. The primary outcome is the effectiveness of JDTLG on depression after 8 weeks treatment, which is defined as a decrease of 50% or more in 17-item Hamilton Depression Scale (HAMD-17) score or clinical recovery (score < 7). Secondary outcomes are improvement in neurological function, degree of independence, activities of daily living, and TCM syndrome at each visit, which will be measured with National Institute of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Barthel Index (BI) and TCM scale, respectively. Interleukin (IL)-6, IL-8, and small-molecule metabolites will be monitored to explore the mechanism of action of JDTLG on PSD. Safety measures include vital signs, results of electrocardiography, laboratory index (full blood count, kidney and liver function tests) and adverse events. DISCUSSION: The purpose of this trial is to evaluate the therapeutic effects and safety of JDTLG in individuals with PSD with concomitant qi deficiency and blood stasis syndrome. If successful, the outcome of this trial will provide a viable treatment option for PSD patients. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT03147053 . Registered on 27 April 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhao AM, Qiu WR, Mao LJ, et al. The efficacy and safety of Jiedu Tongluo granules for treating post-stroke depression with qi deficiency and blood stasis syndrome: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29747670. doi:10.1186/s13063-018-2633-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。